Literature DB >> 23612426

Differences in perfusion CT parameter values with commercial software upgrades: a preliminary report about algorithm consistency and stability.

Maria Antonietta Mazzei1, Nevada Cioffi Squitieri, Eleonora Sani, Susanna Guerrini, Giusi Imbriaco, Duccio Di Lucia, Andrea Guasti, Francesco Giuseppe Mazzei, Luca Volterrani.   

Abstract

BACKGROUND: Computed tomographic perfusion (CTp) imaging is a promising technique that allows functional imaging, as an adjunct to a morphologic CT examination, that can be used as an aid to carefully evaluate the response to therapy in oncologic patients. Considering this statement, it could be desirable that the measurements obtained with the CT perfusion software, and their upgrades, are consistent and reproducible.
PURPOSE: To determine how commercial software upgrades impact on algorithm consistency and stability among the three version upgrades of the same platform in a preliminary study.
MATERIAL AND METHODS: Blood volume (BV), blood flow (BF), mean transit time (MTT), and permeability surface area product (PS) were calculated with repeated measurements (n = 1119) while truncating the time density curve at different time values in six CT perfusion studies using CT perfusion software version 4D (CT Perfusion 4D), then repeated with the previous version (CT Perfusion 3.0 and CT Perfusion 4.0), using a fixed ROI both for arterial input and target lesion. The software upgrades were compared in pairs by applying a Kolmogorov-Smirnov test to all the parameters measured. Stability and reliability of the three versions were verified through the variation of the truncated parameters.
RESULTS: The three software versions provided different parent distributions for approximately 80% of the 72 parameters measured. A complete agreement was found only for one patient in version 3.0 vs. 4.0 and 3.0 vs. 4D. Perfusion 4.0 vs. 4D: a complete agreement was found only in two cases. Parameters obtained with Perfusion 4D always showed the lowest standard deviation in all temporal intervals and also for all individual parameters.
CONCLUSION: The three versions of the same platform tested yield different perfusion measurements. Thus, our preliminary results show that Perfusion 4D version uses a stable deconvolution algorithm to provide more reliable measurements.

Entities:  

Keywords:  Perfusion imaging; multidetector computed tomography; oncology; software

Mesh:

Substances:

Year:  2013        PMID: 23612426     DOI: 10.1177/0284185113484643

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  14 in total

1.  Use of patient outcome endpoints to identify the best functional CT imaging parameters in metastatic renal cell carcinoma patients.

Authors:  Jill Rachel Mains; Frede Donskov; Erik Morre Pedersen; Hans Henrik Torp Madsen; Jesper Thygesen; Kennet Thorup; Finn Rasmussen
Journal:  Br J Radiol       Date:  2018-01-02       Impact factor: 3.039

2.  Dynamic perfusion CT - A promising tool to diagnose pancreatic ductal adenocarcinoma.

Authors:  Inga Zaborienė; Giedrius Barauskas; Antanas Gulbinas; Povilas Ignatavičius; Saulius Lukoševičius; Kristina Žvinienė
Journal:  Open Med (Wars)       Date:  2021-02-05

3.  CT perfusion: technical developments and current and future applications.

Authors:  Maria Antonietta Mazzei; Lorenzo Preda; Alessandro Cianfoni; Luca Volterrani
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

4.  Detection of small (≤ 2 cm) pancreatic adenocarcinoma and surrounding parenchyma: correlations between enhancement patterns at triphasic MDCT and histologic features.

Authors:  Michele Scialpi; Lucio Cagini; Luisa Pierotti; Francesco De Santis; Teresa Pusiol; Irene Piscioli; Michelle Magli; Alfredo D'Andrea; Luca Brunese; Antonio Rotondo
Journal:  BMC Gastroenterol       Date:  2014-01-21       Impact factor: 3.067

5.  Assessment of renal function in patients with unilateral ureteral obstruction using whole-organ perfusion imaging with 320-detector row computed tomography.

Authors:  Xiang-Ran Cai; Qing-Chun Zhou; Juan Yu; You-Zhen Feng; Zhao-Hui Xian; Wen-Cai Yang; Xu-Kai Mo
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

6.  CT perfusion in the characterisation of renal lesions: an added value to multiphasic CT.

Authors:  Francesco Giuseppe Mazzei; Maria Antonietta Mazzei; Nevada Cioffi Squitieri; Chiara Pozzessere; Lorenzo Righi; Alfredo Cirigliano; Susanna Guerrini; Domenico D'Elia; Maria Raffaella Ambrosio; Aurora Barone; Maria Teresa del Vecchio; Luca Volterrani
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

7.  Reduced time CT perfusion acquisitions are sufficient to measure the permeability surface area product with a deconvolution method.

Authors:  Francesco Giuseppe Mazzei; Luca Volterrani; Susanna Guerrini; Nevada Cioffi Squitieri; Eleonora Sani; Gloria Bettini; Chiara Pozzessere; Maria Antonietta Mazzei
Journal:  Biomed Res Int       Date:  2014-08-12       Impact factor: 3.411

8.  CT-perfusion measurements in pancreatic carcinoma with different kinetic models: Is there a chance for tumour grading based on functional parameters?

Authors:  Sven Schneeweiß; Marius Horger; Anja Grözinger; Konstantin Nikolaou; Dominik Ketelsen; Roland Syha; Gerd Grözinger
Journal:  Cancer Imaging       Date:  2016-12-15       Impact factor: 3.909

9.  Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer).

Authors:  Maria Antonietta Mazzei; Letizia Di Giacomo; Giulio Bagnacci; Valerio Nardone; Francesco Gentili; Gabriele Lucii; Paolo Tini; Daniele Marrelli; Paolo Morgagni; Gianni Mura; Gian Luca Baiocchi; Frida Pittiani; Luca Volterrani; Franco Roviello
Journal:  Quant Imaging Med Surg       Date:  2021-06

10.  Perfusion in the tissue surrounding pancreatic cancer and the patient's prognosis.

Authors:  Yoshihiro Nishikawa; Yoshihisa Tsuji; Hiroyoshi Isoda; Yuzo Kodama; Tsutomu Chiba
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.